ALC241220P87500
- 0.95
- -0.35-26.92%
Alcon Newsroom
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Alcon (ALC)
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $107.25
Deutsche Bank Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $92.9
J.P. Morgan Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $89.5
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and ScPharmaceuticals (SCPH)
BofA Securities Maintains Alcon(ALC.US) With Hold Rating, Cuts Target Price to $93.63
Jefferies Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $100
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $93.63 to $107
KeyBanc Sticks to Their Buy Rating for Alcon (ALC)
Alcon's Strong Market Position and Growth Prospects Underscore Buy Rating
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $97.06 to $107
Alcon's Mixed Q3 Performance and Product Pipeline Drive Hold Rating
Alcon Analyst Ratings
Alcon's Strategic Growth Potential and Market Position Justify Buy Rating
Wells Fargo Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $105
Kepler Cheuvreux Upgrades Alcon to Hold From Reduce, Adjusts Price Target to $235 From $205
RBC Capital Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $115.62
Baird Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $110
Alcon's Strong Market Position and Promising 2025 Product Launches Justify Buy Rating
Stifel Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100